Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP

Ophthalmic Surg Lasers Imaging Retina. 2019 Jun 1;50(6):337-343. doi: 10.3928/23258160-20190605-01.


Background and objective: To evaluate neurodevelopmental outcomes among infants treated for retinopathy of prematurity (ROP) at the authors' institution.

Patients and methods: Before-and-after retrospective chart reviews identified 40 infants treated with laser and 46 treated with primary intravitreal bevacizumab (IVB). Primary outcomes were death, hearing loss, bilateral visual impairment (BVI), and cerebral palsy (CP); odds ratios (ORs) were calculated to determine factors associated with CP. Secondary outcomes were mean Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) scores.

Results: Overall, there were no significant differences in primary outcome measures by treatment group. However, adjusted odds of BVI were significantly higher with laser compared to IVB (OR = 13.1; P = .038). Although IVB was not associated with CP, both hydrocephalus and BVI were strongly correlated with CP. Mean Bayley-III scores were similar when comparing nine laser-treated infants to 13 IVB-treated infants.

Conclusions: Visual outcomes are an important aspect of neurodevelopment. IVB was not associated with severe developmental disabilities and may protect against vision loss in this analysis. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:337-343.].

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use*
  • Bevacizumab / adverse effects
  • Bevacizumab / therapeutic use*
  • Cerebral Palsy / epidemiology
  • Female
  • Hearing Loss / epidemiology
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intravitreal Injections
  • Laser Coagulation / methods*
  • Male
  • Odds Ratio
  • Retinopathy of Prematurity* / drug therapy
  • Retinopathy of Prematurity* / mortality
  • Retinopathy of Prematurity* / surgery
  • Retrospective Studies
  • Vision, Low / epidemiology


  • Angiogenesis Inhibitors
  • Bevacizumab